The DOI matches its Crossref record; 63 of the 70 references it cites were found in a registry or an index.
Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1α
Open accessAbstract
The switch to an angiogenic phenotype is a fundamental determinant of neoplastic growth and tumor progression. We demonstrate that homozygous deletion of the p53 tumor suppressor gene via homologous recombination in a human cancer cell line promotes the neovascularization and growth of tumor xenografts in nude mice. We find that p53 promotes Mdm2-mediated ubiquitination and proteasomal degradation of the HIF-1α subunit of hypoxia-inducible factor 1 (HIF-1), a heterodimeric transcription factor that regulates cellular energy metabolism and angiogenesis in response to oxygen deprivation. Loss of p53 in tumor cells enhances HIF-1α levels and augments HIF-1-dependent transcriptional activation of the vascular endothelial growth factor (VEGF) gene in response to hypoxia. Forced expression of HIF-1α in p53-expressing tumor cells increases hypoxia-induced VEGF expression and augments neovascularization and growth of tumor xenografts. These results indicate that amplification of normal HIF-1-dependent responses to hypoxia via loss of p53 function contributes to the angiogenic switch during tumorigenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Apart from canonical HRE-mediated transcription, the HIF isoforms differentially modulate signaling pathways through interaction with proteins that do not contain PAS domains, such p53, the c-MYC proto-oncogene, β-catenin and the Notch intracellular domain (Fig. 2A) [11–15].”
From Revisiting the HIF switch in the tumor and its immune microenvironment. (2022) · cites this paper as [11]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Intriguingly, p53 can also promote Mdm2-mediated degradation of HIF-1α (Ravi et al., 2000).”
From Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer (2016) · cites this paper as Ravi et al., 2000
The cited source says what the claim attributes to it.
In the citing paper
“It has been proposed that MDM2 can also ubiquitinate and degrade HIF-1α through the proteasome pathway”
From Stress Response of Glioblastoma Cells Mediated by miR-17-5p Targeting PTEN and the Passenger Strand miR-17-3p Targeting MDM2 (2012) · cites this paper as [56]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“which raises the possibility that miR-17 mediates cellular response to diverse stimuli by targeting closely related signaling pathways [56].”
From Stress Response of Glioblastoma Cells Mediated by miR-17-5p Targeting PTEN and the Passenger Strand miR-17-3p Targeting MDM2 (2012) · cites this paper as [56]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hershko, A., & Ciechanover, A. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.425 · Cited by 8,840
p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
Hanahan, D., & Folkman, J. (1996) · Cell · doi:10.1016/s0092-8674(00)80108-7 · Cited by 6,885
Wang, G. L., Jiang, B. H., Rue, E. A., & Semenza, G. L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.12.5510 · Cited by 6,212
Self-citationThe tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180
Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
Shweiki, D., Itin, A., Soffer, D., & Keshet, E. (1992) · Nature · doi:10.1038/359843a0 · Cited by 4,617
The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53
Scheffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. J., & Howley, P. M. (1990) · Cell · doi:10.1016/0092-8674(90)90409-8 · Cited by 3,995
Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1
Forsythe, J. A., Jiang, B.-H., Iyer, N. V., Agani, F., Leung, S. W., Koos, R. D., & Semenza, G. L. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.9.4604 · Cited by 3,981
Self-citationKim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., & Ferrara, N. (1993) · Nature · doi:10.1038/362841a0 · Cited by 3,605
Regulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312 · cited 1×
“…ligase and is itself a target for Ub-mediated degradation via its interaction with Mdm2 (Momand et al. 1992; Barak et al. 1993; Wu et al. 1993; Haupt et al. 1997; Honda et al. 1997; Kubbutat et al. 1997), this raised the possibility that HIF-1a is recruited to Mdm2 via its interaction with p53.”
Background
Flagged first, then by citations
7 of the 70 references couldn’t be matched to a known paper.
Research works printed but not linked: 3
- Kubbutat, 1997, Regulation of p53 stability by Mdm2., Nature, 387, 299, 10.1038/387299a0 · DOI · Paper page
- Ravi, 1998, p53-mediated repression of nuclear factor κ-B RelA via the transcriptional integrator p 300., Cancer Res., 58, 4531
- Zhong, 1999, Overexpression of hypoxia-inducible factor 1α in common human cancers and their metastases., Cancer Res., 59, 5830
Cited by
Sorted by citations
Items 901–967 of 967
Hautanen, V., Toimela, T., Paparella, M., & Heinonen, T. (2023) · Alternatives to Laboratory Animals · doi:10.1177/02611929231171165 · Cited by 2
HIF‐1 Inhibitors for Cancer Therapy
Rapisarda, A., & Melillo, G. (2010) · Wiley eBooks · doi:10.1002/9780470669891.ch17 · Cited by 1
Modeling wild type and mutant p53 in telomerase-immortalized human cellsPreprint
Miciak, J. J., & Bunz, F. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.06.22.546141 · Cited by 1
The novel curcumin analogue AKT-100 targets both mutant p53 and STAT3 in gynecologic cancer cellsPreprint
Williams, G. L., Smith, L. E., Padilla, J. L., Goss, A., Belmares-Ortega, D., Wu, X., Daw, J., Mitra, S., Jagtap, P. G., Monts, J. K., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.06.680794 · Cited by 1
Kumar, R., Couly, S., Muys, B. R., Li, X. L., Grammatikakis, I., Singh, R., Guest, M., Wen, X., Tang, W., Ambs, S., et al. (2025) · eLife · doi:10.7554/elife.107538 · Cited by 1
Cellular Respiration and Tumor Suppressor Genes
Gonzalez‐Cuyar, L. F., Tavora, F. R. F., Caminha, I., Perry, G. L., Smith, M. A., & Castellani, R. J. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-435-3_10
von Hippel-Lindau Tumor Suppressor, Hypoxia-Inducible Factor-1, and Tumor Vascularization
Zhang, H., & Semenza, G. L. (2009) · Springer eBooks · doi:10.1007/978-1-4419-0711-0_6
Self-citationPera, M., Volant, A., Fondevila, C., Metges, J. P., Vidal, Ó., & Palacı́n, A. (2005) · Handbook of immunohistochemistry and in situ hybridization of human carcinomas · doi:10.1016/s1874-5784(05)80065-0
Protein factors and chemical compounds regulating hypoxic or oxidative stress responses
Oguro, A., Kobayashi, Y., & Imaoka, S. (2015) · Personalized Medicine Universe · doi:10.1016/j.pmu.2015.04.004
Targeting Hypoxic Adaptations of Cancer Cells: Molecular Mechanisms and Therapeutic Opportunities
Tang, C., & Yu, J. Q. (2014) · Springer eBooks · doi:10.1007/978-94-017-9421-3_14
Acker, T., & Plate, K. H. (2006) · Elsevier eBooks · doi:10.1016/b978-012088410-0/50053-6
Bando, Y., & Murohara, T. (2012) · Circulation Journal · doi:10.1253/circj.cj-12-0200
Targeting hypoxia-inducible factor-1 for therapy and prevention
Zhong, H. (2004) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.14.7.951
Staibano, S., & Ascierto, P. A. (2013) · Springer eBooks · doi:10.1007/978-94-007-7149-9_14
Hypoxia and Angiogenesis in Glioblastomas
Acker, T., & Plate, K. H. (2007) · Springer eBooks · doi:10.1007/978-3-540-33177-3_11
Oxygen-Dependent Regulation of Erythropoiesis
Haase, V. H. (2010) · Humana Press eBooks · doi:10.1007/978-1-60761-857-7_23
Molecular Basis of “Hypoxic” Signaling, Quiescence, Self-Renewal, and Differentiation in Stem Cells
Ivanović, Z., & Vlaski‐Lafarge, M. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800540-8.00007-7
Role of c-Myc and CD34 oncoproteins expression in early and late phases of hepatocarcinogenesis
El-maksoud, A. A. A., & Elazez, T. A. E. A. (2011) · Egyptian Journal of Pathology · doi:10.1097/01.xej.0000398108.88640.3f
Targeting Cancer Stem Cells and the Tumor Microenvironment
Turdo, A., Todaro, M., & Stassi, G. (2015) · Springer eBooks · doi:10.1007/978-3-319-21030-8_16 · Cited by 1
Hypoxia-Induced Factor-1 as a Target for Anticancer Therapy
Bhattacharya, S. (2002) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-1-59259-153-4_4
Human Papillomaviruses and Mechanisms of Oncogenesis
Roman, A., Spartz, H., & Brown, D. R. (2008) · Elsevier eBooks · doi:10.1016/b978-1-4160-3405-6.10002-2
STUDY OF EXPRESSION P16INK4A, KI-67, VEGF AND E-CADHERIN SQUAMOUS INTRAEPITHELIAL LESIONS OF CERVIX
Shamarakova, M. V., & Shamarakova, M. V. (2011) · I P Pavlov Russian Medical Biological Herald · doi:10.17816/pavlovj201123-3
Molecular Basis for Vascular Endothelial Growth Factor Expression in Tumor
Xie, K., & Yao, J. C. (2008) · Springer eBooks · doi:10.1007/978-1-4020-8341-9_6
Tissue-Based Biomarkers of Tumor-Vascular Interactions
Akslen, L. A. (2017) · Springer eBooks · doi:10.1007/978-3-319-39147-2_3
Curcumin: Its Role in Regulation of HIF-1α in Gastric Cancer
Barik, T. K., & Swain, S. N. (2017) · Springer eBooks · doi:10.1007/978-981-10-6728-0_14
The Value of Anti-angiogenics in Cervical Cancer Therapy
Erbes, T., Farthmann, J., & Berner, K. (2019) · Springer eBooks · doi:10.1007/978-3-319-33673-2_26
Yin and Yang of YY1 regulation on tumor metabolic reprogramming
Meliala, I. T. S., Hosea, R., Kasim, V., & Wu, S. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821909-6.00014-6
Hypoxia Inducible Factor-1 and VEGF Induction
Madan, A. (2008) · Springer eBooks · doi:10.1007/978-1-4020-6780-8_9
Self-citationHeymach, J. V., Zurita‐Saavedra, A., Kopetz, S., Cascone, T., & Nilsson, M. B. (2017) · Wiley eBooks · doi:10.1002/9781119000822.hfcm017
Hypoxia-Induced Cytosine Deaminase Gene Expression for Cancer Therapy
Lee, C., Wu, C., & Shiau, A. (2006) · Human Gene Therapy · doi:10.1089/hum.2006.18.ft-275
The Value of Anti-angiogenics in Cervical Cancer Therapy
Erbes, T., Farthmann, J., & Berner, K. (2018) · Springer eBooks · doi:10.1007/978-3-319-31215-6_26-1
Šupolíková, M., Novakova, E., Donátová, K., Olejníková, P., & Labudová, M. (2023) · Pathogens and Disease · doi:10.1093/femspd/ftad004
Kong, D., Park, E., Stephen, A. G., Calvani, M., Cardellina, J. H., Monks, A. P., Fisher, R. J., Shoemaker, R. H., & Melillo, G. (2023) · doi:10.1158/0008-5472.22365320
The Expression and Correlation of Pin1 and VEGF in Lung Cancer
王, 珊. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.1361409
Kumar, R. S., Couly, S., Muys, B. R., Li, X. L., Grammatikakis, I., Singh, R., Guest, M., Wen, X., Tang, W., Ambs, S., et al. (2025) · eLife · doi:10.7554/elife.107538.1
Efficacy analysis of targeted P53 therapy in solid tumors
Wang, P., & Wang, F. (2025) · Medical Oncology · doi:10.1007/s12032-025-02930-y
Mapping the HIF Transcription Factor in Cancer by ChIP-Seq Technology
Schödel, J., & Mole, D. R. (2013) · Springer eBooks · doi:10.1007/978-1-4614-7645-0_5
Additional file 1 of The implication of serum HLA-G in angiogenesis of multiple myeloma
Wang, C., Su, N.-W., Hsu, K., Kao, C.-W., Chang, M.-C., Chang, Y.-F., Lim, K.-H., Chiang, Y.-H., Chang, Y.-C., Sung, M.-T., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26043769
Kumar, R. S., Couly, S., Muys, B. R., Li, X. L., Grammatikakis, I., Singh, R., Guest, M., Wen, X., Tang, W., Ambs, S., et al. (2026) · eLife · doi:10.7554/elife.107538.2
Li, X., Zhang, X., Dai, Y., Huang, F., Wei, R., Huang, X., Ma, D., Li, F., & Li, X. (2026) · BMC Cancer · doi:10.1186/s12885-026-15597-z
Zhang, F., Zheng, Z., Zhang, H., Yan, X., Liu, Z., Yang, F., Wen, J., Gan, X., Wu, L., Cang, S., et al. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02550-y
1,2-propanediol ameliorated radiation-induced intestinal injury in mice
Zhao, J., Zhao, C., Shen, X., Jiang, Y., Wang, X., Ji, A., Zhang, X., Xing, S., Sun, G., Xiao, H., et al. (2026) · Scientific Reports · doi:10.1038/s41598-026-43614-5
Influence of hypoxia on tumour cell susceptibility to cytotoxic T lymphocyte mediated lysis
Noman, M. Z. (2012) · theses.fr (ABES) · doi:10.70675/306da2eez5bc3z478ez83c5zdc39407a896e
Guerrab, A. E. (2011) · theses.fr (ABES) · doi:10.70675/0680d6aez5ddfz48efzabe9zf58f93e15842
Les plasmas froids, nouvelle stratégie thérapeutique en cancérologie
Vandamme, M. (2012) · theses.fr (ABES) · doi:10.70675/6c208bb1zfa66z4b33z8b69z39f1f07a523f
Impact des facteurs de restriction sur la réplication du virus de l'hépatite B
Hallez, C. (2017) · theses.fr (ABES) · doi:10.70675/0382f2a3zfb90z4c82zb723za9e5e5b1952b
Role of VDAC1 hypoxic form, VDAC1-∆C, in the expression of primary cilia and tumor progression
Fabbri, L. (2019) · theses.fr (ABES) · doi:10.70675/7a53239dzc652z4ea4z8b95z4a71961c83b4
Chaddad, H. (2019) · theses.fr (ABES) · doi:10.70675/e2786a5az288az46d4za2afz98cdafddfe5b
Impact du ciblage du domaine de liaison de HIF-1α avec HIF-1β sur le paysage immunitaire du mélanome
Lequeux, A. (2020) · theses.fr (ABES) · doi:10.70675/a29d12dbz79c1z4d37za978z2e2319131c82
P53 – a new player in the metabolic adaptation of colorectal carcinoma cells under hypoxia
Saoub, S., Metzen, E., Thakur, B. K., Henning, Y., Schild, Y., Leu, T., Fandrey, J., & Wrobeln, A. (2026) · BMC Cancer · doi:10.1186/s12885-026-16184-y
Silveria, S. L., Peeters, J. G. C., Vickery, J., Veronezi, G. M. B., Ramachandran, S., & DuPage, M. J. P. (2026) · The Journal of Immunology · doi:10.1093/jimmun/vkag145
O 2 -sensing and HIF regulation: from oxygen homeostasis to tumor-associated immune responses
Schneider, V., Fandrey, J., & Winning, S. (2026) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00185.2026
Sultana, F., De, A., Bose, S., Roychowdhury, A., Khatun, M., Chatterjee, P., Vernekar, M., Banerjee, D., Chakrabarti, J., Mandal, R., et al. (2026) · Genetic Testing and Molecular Biomarkers · doi:10.1177/19450265261491098
Ho, P. T. H., Nguyen, D. D., Vương, Đ. T. H., Tran, G. H., Trung, L. V., Hoang, T. V., & Nguyen, H. B. (2026) · Cancer Reports · doi:10.1002/cnr2.70701
Jing, X., Ma, M., Bai, Y., Wu, Y., Sun, X., Wu, J., Holgersson, K., Wang, X., Chen, L., Long, S., et al. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02952-6
Haque, S., Purohit, S., Sharma, S., & Singh, P. (2026) · In Silico Research in Biomedicine · doi:10.1016/j.insi.2026.100688
BindingDB (2021) · UC San Diego · doi:10.7270/q2xk8jw5
BindingDB Entry 50040848: Recent advances in hypoxia-inducible factor (HIF)-1 inhibitors.
BindingDB (2013) · UC San Diego · doi:10.7270/q26d5v4n
Regulation of Angiogenesis by Androgen-Responsive Gene EAF2
Pascal, L. E., & Wang, Z. (2013) · Springer eBooks · doi:10.1007/978-1-4614-6182-1_17
Oncogenes, Anti-Oncogenes, and Genetic Regulators of Vascular Development
Lane, T. F., & Collado-Hidalgo, A. (2001) · Birkhäuser Boston eBooks · doi:10.1007/978-1-4612-0213-4_5
Role of Brain Microenvironment in Brain Metastases
Grunfeld, J., & Puduvalli, V. K. (2005) · Springer eBooks · doi:10.1007/1-4020-3414-8_7
Metadata
- Authors
- Ravi, R., Mookerjee, B., Bhujwalla, Z. M., Sutter, C. H., Artemov, D., Zeng, Q., Dillehay, L. E., Madan, A., Semenza, G. L., & Bedi, A.
- Affiliations
- Johns Hopkins University (US)
- Venue
- Genes & Development
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2000-01-01
- Volume
- 14
- Issue
- 1
- Pages
- 34-44
- ISSN
- 0890-9369 (ISSN-L)
- 1549-5477
- OpenAlex
- W4294718043
- Semantic Scholar
- 5c0770cda1be256df47794076979768b0350af33
- Cited by
- 967
- References
- 70
- Citations by year
- 2026: 19 · 2025: 23 · 2024: 35 · 2023: 28 · 2022: 35 · 2021: 35 · 2020: 33 · 2019: 25 · 2018: 30 · 2017: 25 · 2016: 35 · 2015: 41 · 2014: 36 · 2013: 34 · 2012: 32
- Type
- posted content
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Genes & Development (publishedVersion)
- Funders
- U.S. Department of Defense
- American Cancer Society
- National Institutes of Health
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- tumor angiogenesis, p53, hypoxia-inducible factor-1α, MDM2, ubiquitination, proteasomal degradation, vascular endothelial growth factor, hypoxia, neovascularization, tumor xenografts, angiogenic switch, tumor suppressor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
